Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease… (NCT07177352) | Clinical Trial Compass
RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
United States13,000 participantsStarted 2025-07-02
Plain-language summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Who can participate
Age range50 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
\- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.
Exclusion Criteria:
* Dependency in basic activities of daily living (bADLs) due to cognitive impairment
* Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
* Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
* History of severe, clinically significant central nervous system trauma
* Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
What they're measuring
1
Concentration of pTau217 in Blood on Day1
Timeframe: Day 1
2
Cognitive score in ISLT on Day 1
Timeframe: Day 1
Trial details
NCT IDNCT07177352
SponsorHoffmann-La Roche
Sponsor typeINDUSTRY
Study typeINTERVENTIONAL
Primary completion2035-07-31
Contact for this trial
Reference Study ID Number: WP45722 https://forpatients.roche.com/